Ваш мозг. Что нейронаука знает о мозге и его причудах - Марк Дингман

28 X. Wang, L. Zhang, Y. Lei, X. Liu, X. Zhou, Y. Liu, M. Wang, et al., “Meta-Analysis of Infectious Agents and Depression,” Scientific Reports 4 (2014): 4530.

29. M. Lucas, F. Mirzaei, A. Pan, O.I. Okereke, W.C. Willett, E.J. O’Reilly, K. Koenen, and A. Ascherio, “Coffee, Caffeine, and Risk of Depression among Women,” Archives of Internal Medicine 171, no. 17 (September 2011): 1571–1578.

30. H. Hedegaard, S.C. Curtin, and M. Warner, “Suicide Mortality in the United States, 1999–2017,” NCHS Data Brief 330 (November 2018): 1–7.

1. J. Cole, Pride and a Daily Marathon (Massachusetts: The MIT Press, 1991).

2. G. Fritsch and E. Hitzig, “Electric Excitability of the Cerebrum (Uber die elektrische Erregbarkeit des Grosshirns),” Epilepsy & Behavior 15, no. 2 (June 2009): 123–130.

3. M. Omrani, M.T. Kaufman, N.G. Hatsopoulos, and P.D. Cheney, “Perspectives on Classical Controversies about the Motor Cortex,” Journal of Neurophysiology 118, no. 3 (September 2017): 1828–1848.

4. F.A. Azevedo, L.R. Carvalho, L.T. Grinberg, J.M. Farfel, R.E. Fer-retti, R.E. Leite, W Jacob Filho, R. Lent, and S. Herculano-Houzel, “Equal Numbers of Neuronal and Nonneuronal Cells Make the Human Brain an Isometrically Scaled-Up Primate Brain,” Journal of Comparative Neurology 513, no. 5 (April 2009): 532–541.

5. H.C. Cheng, C.M. Ulane, and R.E. Burke, “Clinical Progression in Parkinson Disease and the Neurobiology of Axons,” Annals of Neurology 67, no. 6 (June 2010): 715–725.

6. C.A. Davie, “A Review of Parkinson’s Disease,” British Medical Bulletin 86 (2008): 109–127.

7. J. Costa, N. Lunet, C. Santos, J. Santos, and A. Vaz-Carneiro, “Caffeine Exposure and the Risk of Parkinson’s Disease: A Systematic Review and Meta-Analysis of Observational Studies,” Journal of Alzheimers Disease 20, Suppl. 1 (2010): S221-S238.

8. M.A. Hernan, B. Takkouche, F Caamano-Isorna, and J.J. Gestal-Otero, “A Meta-Analysis of Coffee Drinking, Cigarette Smoking, and the Risk of Parkinson’s Disease,” Annals of Neurology 52, no. 3 (September 2002): 276–284.

9. Y. Misu and Y. Goshima, “Is L-dopa an Endogenous Neurotransmitter?” Trends in Pharmacological Sciences 14, no. 4 (April 1993): 119–123.

10. T.A. Newcomer, P.A. Rosenberg, and E. Aizenman, “Iron-Mediated Oxidation of 3,4-Dihydroxyphenylalanine to an Excitotoxin,” Journal of Neurochemistry 64, no. 4 (1995): 1742–1748.

11 G. Porras, P. De Deurwaerdere, Q. Li, M. Marti, R. Morgenstern, R. Sohr, E. Bezard, M. Morari, W.G. Meissnera, “L-Dopa-Induced Dyskinesia: Beyond an Excessive Dopamine Tone In the Striatum,” Scientific Reports 4 (2014): 3730.

1. A.L. Diaz, “Do I Know You? A Case Study Of Prosopagnosia (Face Blindness),” The Journal of School Nursing 24, no. 5 (October 2008): 284–289.

2- I. Kennerknecht, T. Grueter, B. Welling, S. Wentzek, J. Horst, S. Edwards, and M. Grueter, “First Report of Prevalence of Non-Syndromic Hereditary Prosopagnosia (HPA),” American Journal of Medical Genetics Part A 140, no. 15 (August 2006): 1617–1622.

3. J.J.S. Barton and S.L. Corrow, “The Problem of Being Bad at Faces,” Neuropsychologia 89 (August 2016): 119–124.

4. M. Tomasello, B. Hare, H. Lehmann, and J. Call, “Reliance on Head Versus Eyes in the Gaze Following of Great Apes and Human Infants: The Cooperative Eye Hypothesis,” Journal of Human Evolution 52, no. 3 (March 2007): 314–320.

5. K. Koch, J. McLean, R. Segev, M.A. Freed, M.J. Berry, II, V. Bala-subramanian, and P. Sterling, “How Much the Eye Tells the Brain,” Current Biology 16, no. 14 (July 2006): 1428–1434.

6. “Facts about Color Blindness,” National Eye Institute, last modified February 2015, https://nei.nih.gov/health/color_blindness/ facts_about.

7. M. Siniscalchi, S. d’Ingeo, S. Fornelli, and A. Quaranta, “Are Dogs Red-Green Colour Blind?” Royal Society Open Science 4, no. 11 (November 2017): 170869.

8. W.C. Gibson, “Pioneers in Localization of Function in the Brain,” Journal of the American Medical Association 180 (June 1962): 944–951.

9. S. Finger, Origins of Neuroscience (New York: Oxford University Press, 1994).

10. J. Zihl, D. von Cramon, and N. Mai, “Selective Disturbance of Movement Vision after Bilateral Brain Damage,” Brain 106, pt. 2 (June 1983): 313–340.

11. J. Zihl and C.A. Heywood, “The Contribution of LM to the Neuroscience of Movement Vision,” Frontiers in Integrative Neuroscience 9 (February 2015): 6.

12. I. Gauthier, P. Skudlarski, J.C. Gore, and A.W Anderson, “Expertise for Cars and Birds Recruits Brain Areas Involved in Face Recognition,” Nature Neuroscience 3, no. 2 (February 2000): 191–197.

13. E.M. Caves, N.C. Brandley, and S. Johnsen, “Visual Acuity and the Evolution of Signals,” Trends in Ecology & Evolution 33, no. 5 (May 2018): 358–372.

14. B.W. Rovner and R.J. Casten, “Activity Loss and Depression in Age-Related Macular Degeneration,” American Journal of Geriatric Psychiatry 10, no. 3 (May-June 2002): 305–310.

15. A. Moos and J. Trouvain, “Comprehension of Ultra-Fast Speech – Blind Vs. ‘Normally Hearing’ Persons,” Proceedings of the 16th International Congress of Phonetic Sciences (August 2007): 677–680.

16. A. Gordon, Echoes of an Angel: The Miraculous True Story of a Boy Who Lost His Eyes but Could Still See, (Illinois: Tyndale Momentum, 2014).

17. J.J. Chen, H.F. Chang, Y.C. Hsu, and D.L. Chen, “Anton-Babinski Syndrome in an Old Patient: A Case Report and Literature Review,” Psychogeriatrics 15, no. 1 (March 2015): 58–61.

18. N. Kim, D. Anbarasan, and J. Howard, “Anton Syndrome as a Result of MS Exacerbation,” Neurology Clinical Practice 7, no. 2 (April 2017): e19-e22.

1. B.P. Kolla, M.P. Mansukhani, R. Barraza, and J.M. Bostwick, “Impact of Dopamine Agonists on Compulsive Behaviors: A Case Series of Pramipexole-Induced Pathological Gambling,” Psychosomatics 51, no. 3 (May-June 2010): 271–273.

2 J. Olds, “Pleasure Centers in the Brain,” Scientific American 195, no. 4 (October 1956): 105–117.

3. H. De Wit and R.A. Wise, “Blockade of Cocaine Reinforcement In Rats with the Dopamine Receptor Blocker Pimozide, but Not with the Noradrenergic Blockers Phentolamine or Phenoxybenza-mine,” Canadian Journal of Psychology 31, no. 4 (December 1977): 195–203.